2-乙氧基吡啶-3-乙酮 | 62838-66-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-乙氧基吡啶-3-乙酮
• 英文名称: 3-acetyl-2-ethoxypyridine
• 英文别名: Ethoxy-2-acetyl-3-pyridin；3-Acetyl-2-ethoxy-pyridin；1-(2-ethoxy-pyridin-3-yl)-ethanone；1-(2-Ethoxypyridin-3-yl)ethan-1-one；1-(2-ethoxypyridin-3-yl)ethanone
• CAS: 62838-66-8
• 化学式: C₉H₁₁NO₂
• 分子量: 165.192
• InChiKey: ICILFNKGOOEYFQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-乙氧基吡啶-3-乙酮 以81%的产率得到
  参考文献：
  名称：

  SLIWA H.; DELAUNAY L., J. HETEROCYCL. CHEM., 1979, 16, NO 5, 939-944

  摘要：

  DOI：
• 作为产物：
  描述：

  (Ethoxy-2)-nicotinoyl-essigsaeureethylester 在 硫酸 作用下， 以 乙醇 为溶剂， 反应 1.0h， 以57%的产率得到2-乙氧基吡啶-3-乙酮
  参考文献：
  名称：

  Cotterill, W. David; Johnson, David A.; Livingstone, Robert, Journal of Chemical Research, Miniprint, 1995, # 1, p. 221 - 243

  摘要：

  DOI：

文献信息

• [EN] PYRROLIDINE OREXIN RECEPTOR ANTAGONISTS<br/>[FR] COMPOSÉS PYRROLIDINE EN TANT QU'ANTAGONISTES DU RÉCEPTEUR DE L'HYPOCRÉTINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2016095204A1

  公开（公告）日：2016-06-23

  The present invention is directed to pyrrolidine compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及对促进素受体的拮抗剂吡咯烷化合物。本发明还涉及所述化合物在潜在的治疗或预防涉及促进素受体的神经和精神疾病和疾病中的用途。本发明还涉及包含这些化合物的组合物。本发明还涉及这些组合物在潜在的预防或治疗涉及促进素受体的疾病中的用途。
• PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF
  申请人：Rodriguez Martha E.

  公开号：US20110275608A1

  公开（公告）日：2011-11-10

  A method for preventing and/or treating a metabolic disease, cerebrovascular disease, etc. which comprises administering to a mammal an effective amount of the compound of the formula (I): wherein all symbols have the same meanings as defined in the specification; a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof. And a novel compound of the formula (I-1): wherein all symbols have the same meanings as defined in the specification; a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof has an anti-diabetic effect and a neuroprotective effect. Accordingly, the compound of the formula (I) and the compound of the formula (I-1) are useful in a method for preventing and/or treating for a metabolic disease such as diabetes, cerebrovascular disease such as stroke, etc.

  一种预防和/或治疗代谢性疾病、脑血管疾病等的方法，包括向哺乳动物投与公式(I)化合物的有效量：其中所有符号的含义与规范中定义的相同；其盐、N-氧化物、溶剂化物或前药。公式(I-1)的新化合物：其中所有符号的含义与规范中定义的相同；其盐、N-氧化物、溶剂化物或前药具有抗糖尿病和神经保护作用。因此，公式(I)和公式(I-1)的化合物在预防和/或治疗代谢性疾病（如糖尿病）、脑血管疾病（如中风）等方面有用。
• OXAZOLE OREXIN RECEPTOR ANTAGONISTS
  申请人：MERCK SHARP & DOHME CORP.

  公开号：US20160176858A1

  公开（公告）日：2016-06-23

  The present invention is directed to oxazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the oxazole compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及噁唑化合物，其是促进睡眠的荷尔蒙受体的拮抗剂。本发明还涉及这些噁唑化合物在潜在的神经和精神障碍和疾病的治疗或预防中的应用，其中涉及到促进睡眠的荷尔蒙受体。本发明还涉及包含这些化合物的制药组合物。本发明还涉及这些制药组合物在预防或治疗涉及促进睡眠的荷尔蒙受体的疾病中的应用。
• PYRROLIDINE OREXIN RECEPTOR ANTAGONISTS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20170342052A1

  公开（公告）日：2017-11-30

  The present invention is directed to pyrrolidine compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
• 6,5-BICYCLIC OCTAHYDROPYRROLOPYRIDINE OREXIN RECEPTOR ANTAGONISTS
  申请人：Kim Ronald M.

  公开号：US20170320874A1

  公开（公告）日：2017-11-09

  The present invention is directed to 6,5-bicyclic octahydropyrrolopyridine compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.